HCW Biologics entered an exclusive distribution agreement with Akron Biotech to commercialize HCW11-006 as a reagent used to support production of highly functional human CAR-T cells. CAR-T cells are immune cells modified to target specific cells, while a reagent is a substance used in a laboratory or manufacturing process. The announcement did not provide additional commercial terms.